Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Explore the revolutionary ARX-788 antibody-drug conjugate, a precision cancer treatment targeting HER2-positive cancers with unprecedented accuracy and efficacy.